Detailed product-level analysis for benchmarking and improving the performance of medical affairs teams in the US
Clinicians treating severe asthma need the ongoing support of medical affairs teams to ensure complete knowledge of a product’s clinical value and use. The quality of a medical affairs team’s response and service is critical in supporting prescribing and treatment decisions, so how do front-line physicians rate the service they get and where do they see room for improvement?
This and other key questions are answered in this insightful May 2019 analysis of 5 leading severe asthma brands. Based on the results of an in-depth survey of 100 US-based allergists and pulmonologists, Medical Affairs Reputations (US) Targeted Therapies in Severe Asthma (Biologics) identifies the drivers that build clinician satisfaction and brand loyalty.
Medical affairs teams from leading companies in severe asthma assessed
Leading brands covered in this report
Answering important medical affairs performance questions
Exclusive to FirstView, Medical Affairs Reputations surveys reveal, at a brand level, physician satisfaction with the medical affairs services they receive and the key areas where teams can improve their performance
The experience of the physicians surveyed
This detailed analysis is based on a survey of 100 US allergists and pulmonologists with a wealth of experience treating severe asthma. On average they:
This report gives you...
Why FirstView has an edge in pharmaceutical market research
FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.
Other TARGETED THERAPIES IN ASTHMA reports available
Medical Affairs Reputations Europe: Targeted Therapies in Severe Asthma (Biologics)
Market Access Impact US: Targeted Therapies in Severe Asthma (Biologics)
Market Access Impact Europe: Targeted Therapies in Severe Asthma (Biologics)
NPS+ Europe: Targeted Therapies in Severe Asthma (Biologics)
NPS+ Europe: Targeted Therapies in Severe Asthma (Biologics)
Therapy Trends KOL Insight: Targeted Therapies in Asthma
To learn about our cost effective Targeted Therapies in Asthma intelligence package of all reports, please contact us at info@fwreports.com
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved